micro-community-banner
 
  • Saved

September 09, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer - PubMed

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38771995/

First-line ribociclib plus ET showed a significant PFS benefit, similar response rates, and better tolerability over combination CT in patients with clinically aggressive HR+/HER2- ABC.

Ribociclib plus endocrine therapy significantly improved progression-free survival compared to combination chemotherapy in clinically aggressive HR+/HER2- advanced breast cancer, with similar response rates and better tolerability.

Profile Image
  • Saved

September 09, 2024
Impact of bariatric surgery on premenopausal women's womanliness: A qualitative systematic review and meta-synthesis - PubMed

Impact of bariatric surgery on premenopausal women's womanliness: A qualitative systematic review and meta-synthesis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39208194/

Women that have undergone bariatric surgery report several benefits to their health and well-being, although difficulties in adapting mentally to changes in outer appearance need to be managed in order...

Bariatric surgery benefits women by restoring menstruation, improving fertility, and altering fat distribution, but mental adaptation to physical changes remains a challenge.

Profile Image
  • Saved

September 06, 2024
The Menopause Society Annual Meeting

The Menopause Society Annual Meeting is being held Sept. 10 to 14, 2024, in Chicago, and more than 1,300 health care professionals are expected to attend.

The theme of this year’s meeting is Humanizing Artificial Intelligence to Improve Midlife Women’s Health. The program offers updates on artificial intelligence (AI) and the most relevant issues tied to menopause and midlife women’s health, including breast cancer, perimenopause, brain health, hair and skin, bone health, healthy weight, menopause in the workplace, sexuality, substance abuse, and sleep, among other topics.

Click the link above to find out more about the highlights and programs covered during this years Menopause Society Annual Meeting.

  • Saved

September 03, 2024
The complementary roles of iron and estrogen in menopausal differences in cardiometabolic outcomes

The complementary roles of iron and estrogen in menopausal differences in cardiometabolic outcomes

Source : https://pubmed.ncbi.nlm.nih.gov/38593499/

Biological hormonal changes are frequently cited as an explanatory factor of sex and menopause differences in cardiometabolic diseases (CMD) and its associated risk factors. However, iron metabolism which varies between...

Iron's role in cardiometabolic diseases may help explain sex and menopausal differences. Future studies should clarify its mechanistic impact and address current inconsistencies in observational evidence.

Profile Image
  • Saved

September 03, 2024
An effective non-hormonal option with high tolerability for mild to moderate symptoms of vaginal dryness associated with menopause

An effective non-hormonal option with high tolerability for mild to moderate symptoms of vaginal dryness associated with menopause

Source : https://pubmed.ncbi.nlm.nih.gov/38583316/

gov identifier NCT05211505.

The non-hormonal pessary effectively alleviates vaginal dryness symptoms and improves quality of life in postmenopausal women, demonstrating high tolerability and satisfaction with minimal adverse effects.

Profile Image